Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Facial emotion expressivity in patients with Parkinson’s and Alzheimer’s disease ; day:7 ; month:10 ; year:2023 ; pages:1-11
Journal of neural transmission ; (7.10.2023), 1-11
- Urheber
-
Cannavacciuolo, Antonio
Paparella, Giulia
Salzillo, Martina
Colella, Donato
Canevelli, Marco
Costa, Davide
Birreci, Daniele
Angelini, Luca
Guerra, Andrea
Ricciardi, Lucia
Bruno, Giuseppe
Berardelli, Alfredo
Bologna, Matteo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00702-023-02699-2
- URN
-
urn:nbn:de:101:1-2023122821035716299690
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:38 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Cannavacciuolo, Antonio
- Paparella, Giulia
- Salzillo, Martina
- Colella, Donato
- Canevelli, Marco
- Costa, Davide
- Birreci, Daniele
- Angelini, Luca
- Guerra, Andrea
- Ricciardi, Lucia
- Bruno, Giuseppe
- Berardelli, Alfredo
- Bologna, Matteo
- SpringerLink (Online service)
Ähnliche Objekte (12)
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Measuring compounds in exhaled air to detect Alzheimer´s disease and Parkinson´s disease
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
SNAP25 is a potential target for early stage Alzheimer’s disease and Parkinson’s disease
Gene expression meta-analysis of Parkinson’s disease and its relationship with Alzheimer’s disease
Correction to: Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Gray Matter Changes in Parkinson’s and Alzheimer’s Disease and Relation to Cognition
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia
Modeling the neuroimmune system in Alzheimer’s and Parkinson’s diseases
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Measuring compounds in exhaled air to detect Alzheimer´s disease and Parkinson´s disease
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
SNAP25 is a potential target for early stage Alzheimer’s disease and Parkinson’s disease
Gene expression meta-analysis of Parkinson’s disease and its relationship with Alzheimer’s disease
Correction to: Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Gray Matter Changes in Parkinson’s and Alzheimer’s Disease and Relation to Cognition
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia
Modeling the neuroimmune system in Alzheimer’s and Parkinson’s diseases
Parkinson’s disease and Alzheimer’s disease: a Mendelian randomization study
Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Measuring compounds in exhaled air to detect Alzheimer´s disease and Parkinson´s disease
Development of seed amplificafion assays as biomarkers for Alzheimer’s & Parkinson’s disease
SNAP25 is a potential target for early stage Alzheimer’s disease and Parkinson’s disease
Gene expression meta-analysis of Parkinson’s disease and its relationship with Alzheimer’s disease
Correction to: Alzheimer’s disease tau is a prominent pathology in LRRK2 Parkinson’s disease
Gray Matter Changes in Parkinson’s and Alzheimer’s Disease and Relation to Cognition
Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease
Role of glucagon-like peptide-1 receptor agonists in Alzheimer’s disease and Parkinson’s disease
Relevance of plasma biomarkers to pathologies in Alzheimer’s disease, Parkinson’s disease and frontotemporal dementia